SAB Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	56.57	15.05	39.55	12.61	6.35
Cash & Cash Equivalents	56.57	15.05	39.55	12.61	6.35
Cash Growth	275.93%	-61.95%	213.59%	98.71%	-
Receivables	0	5.56	8.01	20.57	2.82
Other Current Assets	2.34	1.49	2.64	1.28	0.12
Total Current Assets	58.91	22.1	50.19	34.46	9.29
Property, Plant & Equipment	24.68	28.34	30.95	22.08	8.71
Other Long-Term Assets	0.35	0.47	0	0	0
Total Long-Term Assets	25.03	28.81	30.95	22.08	8.71
Total Assets	83.94	50.9	81.14	56.54	18
Accounts Payable	0.95	3.68	4.46	7.4	2.18
Deferred Revenue	1.32	0	0.1	0.1	0
Current Debt	1.85	1.4	3.1	1.66	1.95
Other Current Liabilities	6.69	9.92	18.79	1.9	0.49
Total Current Liabilities	10.81	14.99	26.46	11.06	4.62
Long-Term Debt	4.05	4.53	5.42	6.47	5.69
Other Long-Term Liabilities	11.77	0.32	10.72	0	0
Total Long-Term Liabilities	15.83	4.85	16.14	6.47	5.69
Total Liabilities	26.64	19.85	42.59	17.53	10.31
Total Debt	5.91	5.93	8.52	8.13	7.64
Debt Growth	-0.37%	-30.38%	4.80%	6.40%	-
Retained Earnings	-90.06	-47.87	-29.13	-11.98	-32.1
Comprehensive Income	0.03	0	0	0	0
Shareholders' Equity	57.3	31.06	38.55	39.01	-2.31
Net Cash / Debt	50.66	9.12	31.03	4.48	-1.29
Net Cash / Debt Growth	455.59%	-70.61%	591.95%	-	-
Net Cash Per Share	9.17	2.09	11.35	1.66	-0.37
Working Capital	48.09	7.1	23.74	23.39	4.67
Book Value Per Share	10.38	7.14	14.10	15.36	-0.66

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).